RESUMEN
Abciximab occasionally causes severe thrombocytopenia. This is variable in severity and usually occurs within hours of administration but has been reported to present up to 8 days later. This report describes a case of life-threatening thrombocytopenia 16 days following Abciximab administration. The patient required supportive transfusions and ultimately improved following dexamethasone and intravenous immunoglobulin. The case represents the longest delay between Abciximab administration and thrombocytopenia published to date.
Asunto(s)
Anticuerpos Monoclonales/efectos adversos , Fragmentos Fab de Inmunoglobulinas/efectos adversos , Inhibidores de Agregación Plaquetaria/efectos adversos , Trombocitopenia/inducido químicamente , Abciximab , Anciano , Antiinflamatorios/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Transfusión de Sangre Autóloga , Dexametasona/uso terapéutico , Transfusión de Eritrocitos , Humanos , Fragmentos Fab de Inmunoglobulinas/uso terapéutico , Inmunoglobulinas Intravenosas/uso terapéutico , Masculino , Inhibidores de Agregación Plaquetaria/uso terapéutico , Recuento de Plaquetas , Transfusión de Plaquetas , Trombocitopenia/terapia , Factores de Tiempo , Resultado del TratamientoRESUMEN
The minimal inhibitory concentration of azlocillin for Pseudomonas aeruginosa is appreciably reduced when combined with the mucolytic agent mesna (Mistabron) because of an independent bacteriostatic effect of mesna. Bactericidal activity of azlocillin is unaltered by mesna. Mesna inhalations alone or combined with azlocillin may benefit cystic fibrosis patients with pseudomonas lung infections.